lenalidomide has been researched along with Metastase in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Americo, AD; Arcuri, LJ | 1 |
| Chatterjee, S; Kumar, P; Sundaresan, L | 1 |
| Bargetzi, M; Bersvendsen, H; de Nully Brown, P; Dirnhofer, S; Ferreri, AJM; Ghielmini, M; Hagberg, H; Hawle, H; Hayoz, S; Hernberg, M; Hitz, F; Johansson, AS; Kimby, E; Krasniqi, F; Lohri, A; Mey, UJM; Mingrone, W; Novak, U; Rauch, D; Rondeau, S; Vanazzi, A; Vilei, SB; Wahlin, BE; Zander, T; Zucca, E; Østenstad, B | 1 |
| Kiesewetter, B; Lamm, W; Mayerhoefer, ME; Neuper, O; Raderer, M; Simonitsch-Klupp, I | 1 |
| Beck, R; Bencardino, K; Elez, ME; Gandhi, A; Jungnelius, U; Li, M; Prenen, H; Romano, A; Sanchis, M; Sartore-Bianchi, A; Shi, T; Siena, S; Tabernero, J; Tejpar, S; Van Cutsem, E | 1 |
| Agostinelli, C; Argnani, L; Broccoli, A; Celli, M; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Agarwal, N; Apolo, AB; Galsky, MD; Gimpel-Tetra, K; Godbold, JH; Lee, KM; Lowe, N; Oh, WK; Poole, A; Soto, R; Tsao, CK | 1 |
| Abdelrahim, M; Bilen, MA; Erguvan-Dogan, B; Falchook, GS; Fu, S; Hong, DS; Kurzrock, R; Naing, A; Ng, CS; Tsimberidou, AM; Wheler, JJ | 1 |
| Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L | 1 |
| Bartlett, JB; Chen, RS; Hariri, RJ; Hughes, CC; Lu, L; Man, HW; Muller, GW; Payvandi, F; Schafer, PH; Stirling, DI; Wu, L; Zhang, LH | 1 |
| Aragon-Ching, JB; Arlen, PM; Dahut, WL; Figg, WD; Gulley, JL; Tohnya, TM; Ventiz, J; Woo, S; Wright, JJ | 1 |
| Bartlett, JB; Dalgleish, AG; Galustian, C; Henry, JY; Liu, WM; Meyer, B | 1 |
| Agarwala, SS; Atkins, MB; Bedikian, AY; Glaspy, J; Jungnelius, JU; Knight, RD; O'Day, S; Richards, JM | 1 |
| Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U | 1 |
| Bassett, R; Bedikian, A; Hwu, P; Hwu, WJ; Kim, KB; Knight, RD; Papadopoulos, NE; Patnana, M | 1 |
| Arkenau, HT; Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, GT; Lane, CM; Rubin, MS; Spigel, DR; Waterhouse, D | 1 |
| Arlen, PM; Dahut, WL; Figg, WD; Gulley, JL; Ng, SS; Parker, C; Tohnya, TM; Wright, JJ; Zeldis, J | 1 |
| Baz, RC; Bukowski, RM; Choueiri, TK; Dreicer, R; Elson, P; Garcia, JA; Jinks, HA; Mekhail, TM; Rini, BI; Thakkar, SG | 1 |
| Bacik, J; DeLuca, J; Ishill, N; Kondagunta, GV; Motzer, RJ; Patel, PH; Russo, P; Schwartz, L | 1 |
1 review(s) available for lenalidomide and Metastase
| Article | Year |
|---|---|
Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Network Meta-Analysis; Progression-Free Survival; Recurrence | 2021 |
12 trial(s) available for lenalidomide and Metastase
| Article | Year |
|---|---|
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Second Primary; Rituximab; Symptom Assessment; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Thalidomide; Time Factors | 2013 |
Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Lenalidomide; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Thalidomide; Urothelium | 2014 |
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Thalidomide; Treatment Outcome; Valproic Acid | 2015 |
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Thalidomide | 2009 |
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
Topics: Antineoplastic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Retreatment; Skin Neoplasms; Survival Analysis; Thalidomide | 2009 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recurrence; Retreatment; Skin Neoplasms; Thalidomide | 2010 |
Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Survival Rate; Thalidomide | 2010 |
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Rate; Thalidomide | 2013 |
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
Topics: Administration, Oral; Humans; Lenalidomide; Male; Neoplasm Metastasis; Palliative Care; Prostatic Neoplasms; Research Design; Thalidomide | 2004 |
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; Male; Middle Aged; Neoplasm Metastasis; Thalidomide; Treatment Outcome | 2006 |
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Lenalidomide; Male; Middle Aged; Neoplasm Metastasis; Thalidomide; Treatment Outcome | 2008 |
6 other study(ies) available for lenalidomide and Metastase
| Article | Year |
|---|---|
Mechanistic insights into the differential effects of thalidomide and lenalidomide in metastatic prostate cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cholesterol; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lenalidomide; Male; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms; Protein Interaction Mapping; Protein Interaction Maps; Signal Transduction; Thalidomide; Transcriptome | 2018 |
Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Austria; Drug Evaluation; Female; Follow-Up Studies; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Retrospective Studies; Treatment Outcome | 2019 |
Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymph Nodes; Lymphoma, T-Cell; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prednisone; Recurrence; Retreatment; Thalidomide; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Humans; Lenalidomide; Mice; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Perfusion; Pericytes; Thalidomide; Tumor Hypoxia; Xenograft Model Antitumor Assays | 2016 |
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
Topics: Adherens Junctions; Angiogenesis Inhibitors; Animals; Antigens, CD; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; beta Catenin; Cadherins; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; In Vitro Techniques; Lenalidomide; Lung Neoplasms; Melanoma, Experimental; Mice; Microcirculation; Neoplasm Metastasis; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Pregnancy; Proto-Oncogene Proteins c-akt; Thalidomide; Umbilical Arteries | 2009 |
Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs).
Topics: Animals; Antineoplastic Agents; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Immunoblotting; Immunohistochemistry; Immunologic Factors; Lenalidomide; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Invasiveness; Neoplasm Metastasis; Signal Transduction; Thalidomide; Tumor Cells, Cultured | 2009 |